Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward

Stock Information for Xeris Biopharma Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Xeris Biopharma Holdings Inc.

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events
Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital
Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024
Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference
Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.